Clinical Features of Patients With B-CLL
| Patient No. . | Sex . | Age . | Rai Stage . | Lymphocytes (×109/L) . | CD4+/CD8+ Ratio . | Pretreatment Status* . |
|---|---|---|---|---|---|---|
| 1 | M | 74 | 2 | 29.4 | 1.20 | — |
| 2 | F | 78 | 2 | 54.5 | 1.00 | — |
| 3 | M | 56 | 0 | 0.5 | 2.00 | — |
| 4 | M | 76 | 0 | 117.0 | 0.67 | — |
| 5 | M | 66 | 2 | 101.0 | 0.50 | — |
| 6 | M | 73 | 1 | 18.6 | 1.35 | — |
| 7 | M | 58 | 2 | 15.0 | 0.20 | — |
| 8 | M | 60 | 2 | 75.0 | 0.25 | -151 (3 yr) |
| 9 | M | 69 | 1 | 13.0 | 0.26 | -151 (2 yr) |
| 10 | F | 72 | 2 | 64.8 | 0.50 | — |
| 11 | F | 49 | 0 | 77.0 | 1.26 | — |
| 12 | M | 52 | 0 | 23.0 | 1.30 | — |
| 13 | F | 58 | 1 | 105.0 | 2.40 | — |
| 14 | F | 74 | 2 | 40.0 | 0.36 | — |
| 15 | F | 64 | 1 | 9.6 | 3.40 | — |
| 16 | F | 75 | 2 | 20.0 | 0.70 | — |
| 17 | M | 55 | 1 | 9.9 | 0.93 | — |
| 18 | F | 70 | 2 | 77.3 | 0.40 | -151 (16 yr) |
| 19 | M | 70 | 2 | 80.3 | 0.40 | -151 (4 yr) |
| 20 | M | 82 | 2 | 108.0 | 0.30 | -151 (2 yr) |
| 21 | M | 56 | 2 | 14.0 | 0.29 | — |
| 22 | M | 85 | 2 | 78.3 | 0.20 | — |
| 23 | F | 78 | 4 | 162.0 | 0.20 | — |
| 24 | F | 68 | 2 | 119.0 | 0.20 | — |
| 25 | F | 61 | 2 | 28.3 | 0.30 | — |
| 26 | M | 86 | 1 | 28.0 | 1.40 | — |
| 27 | M | 71 | 3 | 75.0 | 0.33 | — |
| 28 | M | 72 | 1 | 81.0 | 1.13 | — |
| 29 | M | 72 | 1 | 91.0 | 0.55 | — |
| 30 | M | 58 | 1 | 72.0 | 2.00 | — |
| 31 | F | 73 | 2 | 81.0 | 1.90 | — |
| 32 | F | 79 | 2 | 100.0 | 1.10 | — |
| 33 | F | 62 | 1 | 93.0 | 0.40 | -151 (5 yr) |
| Patient No. . | Sex . | Age . | Rai Stage . | Lymphocytes (×109/L) . | CD4+/CD8+ Ratio . | Pretreatment Status* . |
|---|---|---|---|---|---|---|
| 1 | M | 74 | 2 | 29.4 | 1.20 | — |
| 2 | F | 78 | 2 | 54.5 | 1.00 | — |
| 3 | M | 56 | 0 | 0.5 | 2.00 | — |
| 4 | M | 76 | 0 | 117.0 | 0.67 | — |
| 5 | M | 66 | 2 | 101.0 | 0.50 | — |
| 6 | M | 73 | 1 | 18.6 | 1.35 | — |
| 7 | M | 58 | 2 | 15.0 | 0.20 | — |
| 8 | M | 60 | 2 | 75.0 | 0.25 | -151 (3 yr) |
| 9 | M | 69 | 1 | 13.0 | 0.26 | -151 (2 yr) |
| 10 | F | 72 | 2 | 64.8 | 0.50 | — |
| 11 | F | 49 | 0 | 77.0 | 1.26 | — |
| 12 | M | 52 | 0 | 23.0 | 1.30 | — |
| 13 | F | 58 | 1 | 105.0 | 2.40 | — |
| 14 | F | 74 | 2 | 40.0 | 0.36 | — |
| 15 | F | 64 | 1 | 9.6 | 3.40 | — |
| 16 | F | 75 | 2 | 20.0 | 0.70 | — |
| 17 | M | 55 | 1 | 9.9 | 0.93 | — |
| 18 | F | 70 | 2 | 77.3 | 0.40 | -151 (16 yr) |
| 19 | M | 70 | 2 | 80.3 | 0.40 | -151 (4 yr) |
| 20 | M | 82 | 2 | 108.0 | 0.30 | -151 (2 yr) |
| 21 | M | 56 | 2 | 14.0 | 0.29 | — |
| 22 | M | 85 | 2 | 78.3 | 0.20 | — |
| 23 | F | 78 | 4 | 162.0 | 0.20 | — |
| 24 | F | 68 | 2 | 119.0 | 0.20 | — |
| 25 | F | 61 | 2 | 28.3 | 0.30 | — |
| 26 | M | 86 | 1 | 28.0 | 1.40 | — |
| 27 | M | 71 | 3 | 75.0 | 0.33 | — |
| 28 | M | 72 | 1 | 81.0 | 1.13 | — |
| 29 | M | 72 | 1 | 91.0 | 0.55 | — |
| 30 | M | 58 | 1 | 72.0 | 2.00 | — |
| 31 | F | 73 | 2 | 81.0 | 1.90 | — |
| 32 | F | 79 | 2 | 100.0 | 1.10 | — |
| 33 | F | 62 | 1 | 93.0 | 0.40 | -151 (5 yr) |
*—Chemonaive patients who never had received chemotherapy.
Patients with prior chemotherapy; the time span between collection of cells and previous treatment is given in parentheses.